Effective Dosage and Administration Schedule of Oral Alendronate for Non-nociceptive Symptoms in Rats with Chronic Constriction Injury

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2010 Jun 2

PMID 20514318

Citations 2

Authors

Sun Im

Seong-Hoon Lim

Jong-In Lee

Young-Jin Ko

Joo Hyun Park

Bo-Young Hong

Geun-Young Park

Affiliations

Soon will be listed here.

Abstract

We evaluated the efficacy of oral alendronate with different dosing regimens for non-nociceptive symptoms and osteoporosis in a sciatic nerve chronic constriction injury (CCI) model. Male Sprague-Dawley rats (n=60) were subdivided into sham control (SC) group and CCI groups, which were divided according to dosage and time of oral alendronate administration: no treatment (NT), low dosage early (LE), high dosage early (HE), low dosage late (LL) and high dosage late (HL). We measured the thickness and temperature of the hind paw, bone mineral density (BMD) of the tibia, along with tibia bone strength. On the 14th day post-CCI, the HE group showed significant reduction in thickness and temperature (P<0.001). On the 42nd day post-CCI, the HE group showed significant reduction in temperature compared to the NT group (P<0.001). Also, both HE and HL groups showed statistically significant increased tibia BMD (P<0.001), along with increase of tibia bone strength compared to the NT group. Based on these findings, early alendronate in high dosages is effective in the non-nociceptive symptoms; early and late alendronate in high dosages, are effective in preventing bone dystrophic changes in a CCI model.

Citing Articles

The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats.

Hedvicakova V, Zizkova R, Buzgo M, Vistejnova L, Klein P, Hovorakova M Int J Nanomedicine. 2023; 18:541-560.

PMID: 36756052 PMC: 9901358. DOI: 10.2147/IJN.S386784.

Can the alendronate dosage be altered when combined with high-frequency loading in osteoporosis treatment?.

Correa C, Camargos G, Chatterjee M, Mesquita M, Del Bel Cury A, Naert I Osteoporos Int. 2016; 28(4):1287-1293.

PMID: 27921147 DOI: 10.1007/s00198-016-3859-1.

References

Kingery W . A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 1998; 73(2):123-139. DOI: 10.1016/S0304-3959(97)00049-3. View

Breuer B, Pappagallo M, Ongseng F, Chen C, Goldfarb R . An open-label pilot trial of ibandronate for complex regional pain syndrome. Clin J Pain. 2008; 24(8):685-9. DOI: 10.1097/AJP.0b013e318175920f. View

Guo T, Wei T, Kingery W . Glucocorticoid inhibition of vascular abnormalities in a tibia fracture rat model of complex regional pain syndrome type I. Pain. 2006; 121(1-2):158-67. DOI: 10.1016/j.pain.2005.12.022. View

Adami S, Fossaluzza V, Gatti D, Fracassi E, Braga V . Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis. 1997; 56(3):201-4. PMC: 1752343. DOI: 10.1136/ard.56.3.201. View

Mackey S, Feinberg S . Pharmacologic therapies for complex regional pain syndrome. Curr Pain Headache Rep. 2007; 11(1):38-43. PMC: 2914598. DOI: 10.1007/s11916-007-0020-z. View

Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M . Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain. 2006; 22(3):235-9. DOI: 10.1097/01.ajp.0000169669.70523.f0. View

Coderre T, Xanthos D, Francis L, Bennett G . Chronic post-ischemia pain (CPIP): a novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat. Pain. 2004; 112(1-2):94-105. DOI: 10.1016/j.pain.2004.08.001. View

Birklein F, Riedl B, Claus D, Neundorfer B . Pattern of autonomic dysfunction in time course of complex regional pain syndrome. Clin Auton Res. 1998; 8(2):79-85. DOI: 10.1007/BF02267817. View

Huygen F, de Bruijn A, Klein J, Zijlstra F . Neuroimmune alterations in the complex regional pain syndrome. Eur J Pharmacol. 2001; 429(1-3):101-13. DOI: 10.1016/s0014-2999(01)01310-3. View

10.

Lee J, Kim J, Kim H, Choi E, Lim S, Jin Ko Y . Changes in bone metabolism in a rat model of traumatic brain injury. Brain Inj. 2005; 19(14):1207-11. DOI: 10.1080/02699050500309338. View

11.

Daemen M, Kurvers H, Bullens P, Barendse G, van Kleef M, van den Wildenberg F . Neurogenic inflammation and reflex sympathetic dystrophy (in vivo and in vitro assessment in an experimental model). Acta Orthop Belg. 1999; 64(4):441-7. View

12.

Varenna M, Zucchi F, Ghiringhelli D, Binelli L, Bevilacqua M, Bettica P . Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol. 2000; 27(6):1477-83. View

13.

van der Laan L, Veldman P, Goris R . Severe complications of reflex sympathetic dystrophy: infection, ulcers, chronic edema, dystonia, and myoclonus. Arch Phys Med Rehabil. 1998; 79(4):424-9. DOI: 10.1016/s0003-9993(98)90144-7. View

14.

Bianchi M, Franchi S, Ferrario P, Sotgiu M, Sacerdote P . Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain. Eur J Pain. 2007; 12(3):284-92. DOI: 10.1016/j.ejpain.2007.06.005. View

15.

Manicourt D, Brasseur J, Boutsen Y, Depreseux G, Devogelaer J . Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum. 2004; 50(11):3690-7. DOI: 10.1002/art.20591. View

16.

Robinson J, Sandom J, Chapman P . Efficacy of pamidronate in complex regional pain syndrome type I. Pain Med. 2004; 5(3):276-80. DOI: 10.1111/j.1526-4637.2004.04038.x. View

17.

Mashiba T, Hirano T, Turner C, Forwood M, JOHNSTON C, Burr D . Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000; 15(4):613-20. DOI: 10.1359/jbmr.2000.15.4.613. View

18.

Kingery W, Offley S, Guo T, Davies M, Clark J, Jacobs C . A substance P receptor (NK1) antagonist enhances the widespread osteoporotic effects of sciatic nerve section. Bone. 2003; 33(6):927-36. DOI: 10.1016/j.bone.2003.07.003. View

19.

Griffin M, Kimble R, Hopfer W, Pacifici R . Dual-energy x-ray absorptiometry of the rat: accuracy, precision, and measurement of bone loss. J Bone Miner Res. 1993; 8(7):795-800. DOI: 10.1002/jbmr.5650080704. View

20.

Goicoechea C, Porras E, Alfaro M, Martin M . Alendronate induces antinociception in mice, not related with its effects in bone. Jpn J Pharmacol. 1999; 79(4):433-7. DOI: 10.1254/jjp.79.433. View